Investors

Corporate Profile
We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.
Stock Quote
ExchangeParis (Euro)
Price€9.50
Change (%) Stock is Down 0.06 (0.63%)
Volume26,934
Data as of 07/20/18 5:35 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle  
17-Jul-2018ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 28, 2018
LYON, France and CAMBRIDGE, Mass., July  17, 2018  (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP) announced that its 2018 Annual General Meeting was held in Lyon on Thursday, June 28, 2018.At the meeting, all resolutions for which management recommended a vote in favor, were adopted, including:                                      ... 
 Printer Friendly Version
24-Jun-2018ERYTECH Confirms Strategic Focus of Eryaspase on Solid Tumors and Ceases Development in Acute Lymphoblastic Leukemia
(GLOBE NEWSWIRE via COMTEX) --- Focuses development efforts on solid tumor indications - Confirms planned launch of company-sponsored randomized Phase 2 trial in first-line pancreatic cancer, in addition to ongoing launch of Phase 3 trial in second-line pancreatic cancer. - Expands eryaspase production capacity in the United States and France - Plans to cease development in acute lymphoblastic leukemia (ALL), including withdrawal of  European Marketing Authorization Application (MAA) ... 
 Printer Friendly Version
20-Jun-2018ERYTECH to Present at JMP Securities Life Science Conference
(GLOBE NEWSWIRE via COMTEX) --LYON, France, June 20, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil Beyen, will present at the JMP Securities Life Science Conference, June 20, 2018 at The St. Regis, New York, in New York City. Conference Details: - Conference:&nbs... 
 Printer Friendly Version
15-Jun-2018ERYTECH to Present Preclinical and Clinical Data on Use of Eryaspase in ALL and AML at EHA 2018
LYON, France, June 15, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present preclinical data on the enzymatic activity of eryaspase (GRASPA®) for the treatment of relapsed acute lymphoblastic leukemia (ALL) and results of its Phase 2b clinical trial evaluating eryaspase (GRASPA®) for the treatment ... 
 Printer Friendly Version
Upcoming EventsMore >>
DateTitle
09/18/18 2:30 p.m. CET
Erytech Pharma Second Quarter 2018 Conference Call and Webcast
11/13/18 2:30 p.m. CET
Erytech Pharma Third Quarter 2018 Conference Call and Webcast
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Erytech Pharma SA posts new information to the site. Just enter your e-mail address and click Submit.
 

ERYTECH Pharma complies with GDPR regulations. For more information about your data, please click here.

Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
Top